TMAO stimulates the transcription factor FoxO1, which is associated with metabolic disease, in the liver by interacting with the endoplasmic reticulum PKR-like eukaryotic initiation factor 2α kinase PERK (EIF2AK3), serving as a receptor. Here, EIF2AK3 is linked to metabolic disease.